Odyssey Therapeutics Appoints Jeremy Sokolove, MD as Chief Medical Officer

BOSTON--(BUSINESS WIRE)--Odyssey Therapeutics, Inc., a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the appointment of Jeremy Sokolove, M.D., as chief medical officer. In this role, Dr. Sokolove will develop, lead and drive the development strategy and execution of all Odyssey’s clinical assets. Additionally, he will be responsible for selecting, prioritizing and accelerating the company’s entire drug development portfolio.

“As the newest member of our executive leadership team, Dr. Sokolove’s medical expertise and background in the biopharmaceutical industry will be critical to the success of our clinical development programs and achieving our corporate goals,” said Gary D. Glick, Ph.D., founder and CEO of Odyssey Therapeutics. “With his vision and leadership, we will continue to improve patient outcomes by delivering life-enhancing precision medicines to those living with inflammatory diseases and cancer.”

Previously, Dr. Sokolove served as senior vice president and head of Clinical Pharmacology and Experimental Medicine at GSK, overseeing all aspects of early and translational development for specialty pharma, as well as companywide clinical pharmacology and imaging. Prior to GSK, he was head of Immunology Translational Science at AbbVie, where he built a portfolio-wide translational medicine strategy and led several early-phase development programs, including the first novel-novel combination study in immunology. Dr. Sokolove also initiated and led phase 3 studies in rheumatoid arthritis and giant cell arteritis, and supported the first global filing of upadacitinib (Rinvoq). Additionally, he served as co-founder of two biotechnology companies, including Atreca, Inc., a publicly traded company in the vaccinology and immuno-oncology space.

Outside of his industry work, Dr. Sokolove was on the faculty in the Division of Immunology and Rheumatology at Stanford University School of Medicine and a primary investigator at the VA Palo Alto Health Care System. For more than 18 years, he has maintained a clinical practice in rheumatology, as well as internal and emergency medicine. In these roles, he has received numerous teaching awards for his contributions to student, resident and fellow education, and has authored numerous patents, abstracts, book chapters, and over 90 peer-reviewed publications.

Dr. Sokolove completed his fellowship and postdoctoral research training in rheumatology and immunology at Stanford Medical Center. He completed his residency and chief residency in internal medicine at Boston University Medical Center and earned his medical degree from Boston University School of Medicine after receiving a Bachelor of Science in biochemistry from the University of New Hampshire.

“It’s an exciting time to join Odyssey as the organization transitions to a clinical-stage biotechnology company,” said Dr. Sokolove. “I look forward to working with a world-class scientific team to implement and execute successful clinical trials to create the next generation of transformative medicines for patients.”

About Odyssey Therapeutics

Odyssey Therapeutics is a biotechnology company focused on discovering, developing and commercializing the next generation of immunomodulators and oncology medicines. Composed of an expert team of drug hunters, scientists and industry leaders in foundational biology, chemistry and data sciences, Odyssey is transforming drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. For more information, please visit odysseytx.com and follow Odyssey Therapeutics on X (formerly Twitter) and LinkedIn.

Media Contact
Michael Sullivan, Spectrum Science
msullivan@spectrumscience.com